Free Trial

2seventy bio Q4 2024 Earnings Report

2seventy bio logo
$4.96 0.00 (0.00%)
As of 12:08 PM Eastern

2seventy bio EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

2seventy bio Revenue Results

Actual Revenue
$2.93 million
Expected Revenue
$12.84 million
Beat/Miss
Missed by -$9.91 million
YoY Revenue Growth
N/A

2seventy bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

2seventy bio Earnings Headlines

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
See More 2seventy bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 2seventy bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 2seventy bio and other key companies, straight to your email.

About 2seventy bio

2seventy bio (NASDAQ:TSVT), a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

View 2seventy bio Profile

More Earnings Resources from MarketBeat